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Abstract
Concurrent chemoradiotherapy (CCRT) has become the standard of care for
patients with unresectable stage III non–small cell lung cancer (NSCLC). The
comparative merits of two widely used regimens: carboplatin/paclitaxel (PC)
and cisplatin/etoposide (PE), each with concurrent radiotherapy, remain largely
undefined. Records for consecutive patients with stage III NSCLC treated with
PC or PE and ≥60 Gy chest radiotherapy between 2000 and 2011 were
reviewed for outcomes and toxicity. Survival was estimated using the Kaplan–
Meier method and Cox modeling with the Wald test. Comparison across
groups was done using the student’s t and chi-squared tests. Seventy-five (PC:
44, PE: 31) patients were analyzed. PC patients were older (median 71 vs.
63 years; P = 0.0006). Other characteristics were comparable between groups.
With PE, there was significantly increased grade ≥3 neutropenia (39% vs. 14%,
P = 0.024) and thrombocytopenia (10% vs. 0%, P = 0.039). Radiation pneu-
monitis was more common with PC (66% vs. 38%, P = 0.033). Five treat-
ment-related deaths occurred (PC: 3 vs. PE: 2, P = 1.000). With a median
follow-up of 51.6 months, there were no significant differences in relapse-free
survival (median PC 12.0 vs. PE 11.5 months, P = 0.700) or overall survival
(median PC 20.7 vs. PE 13.7 months; P = 0.989). In multivariate analyses, no
factors predicted for improved survival for either regimen. PC was more likely to
be used in elderly patients. Despite this, PC resulted in significantly less hemato-
logical toxicity but achieved similar survival outcomes as PE. PC is an acceptable
CCRT regimen, especially in older patients with multiple comorbidities.
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Introduction
Lung cancer accounts for most cancer deaths worldwide,
with the incidence in the developing world set to rise [1].
Most patients are diagnosed with a nonresectable disease,
and 30–40% are considered locally advanced, comprising
both stage IIIA and IIIB.
Concurrent chemoradiotherapy (CCRT) confers a
significant improvement in overall survival (OS)
when compared to sequential chemotherapy followed by
radiotherapy [2, 3], although the incidence of toxicities
such as esophagitis, neutropenia, and anemia are higher
[4]. The rationale behind the combined modality
approach is that radiotherapy provides local tumor eradi-
cation while chemotherapy reduces micrometastatic foci
and is a radiosensitizer. The reported 5-year survival rates
for CCRT, sequential therapy, and radiotherapy alone are
25%, 15%, and less than 10%, respectively [5]. The risk
of locoregional relapse and distant metastasis were lower
in CCRT compared with radiotherapy alone [4].
There are various concurrent chemotherapy combina-
tions that have been trialed, with most using a platinum
compound as a backbone. At present, the optimal CCRT
regimen is not clearly defined. Regimens that have been
used in phase III studies include mitomycin, vindesine, and
cisplatin [2]; etoposide and cisplatin (PE) [3]; vinblastine
and cisplatin [3]; paclitaxel and carboplatin (PC) [6]; as
well as vinorelbine and cisplatin [7]. No randomized phase
III trials, however, have directly compared the different
CCRT regimens, although a recent randomized phase II
trial directly compared PC versus PE with concurrent chest
radiotherapy in a Chinese cohort with unresectable stage
III non–small cell lung cancer (NSCLC) [8].
Our institution has adopted the use of either PE or PC
as standard for Stage III NSCLC. Treatment preference is
largely dictated by age and convenience, with younger
patients and those preferring less frequent chemotherapy
treated as per the SWOG 9019 protocol. We aimed to ret-
rospectively review the efficacy and toxicity for patients
treated at our institution with curative intent radiother-
apy combined with either PE administered according to
the SWOG 9019 protocol or weekly PC.
Methods
Patient population
All patients who consecutively received radical CCRT with
either PC or PE at our institution (Austin Health,
Melbourne, Australia) between 1 January 2000 and 31
December 2011 were identified from our health informa-
tion system, pharmacy, and radiotherapy database. Medical
records were retrospectively reviewed and staging was
determined according to the TNM classification seventh
edition [9]. Clinical stage was determined from computed
tomography (CT) and/or flurodeoxyglucose (18F-FDG)
positron emission tomography (PET) scans, and pathologi-
cal nodal stage from mediastinal or supraclavicular lymph
node biopsy. Only patients with histologically confirmed,
clinical or pathological stage III NSCLC were included in
the study. Patient, tumor, and treatment factors were
recorded, and the severity of patient comorbidities at the
time of diagnosis of cancer was quantified using the
Charlson Comorbidity Index (CCI) [10]. The study was
approved by the Austin Health Research Ethics Committee.
Chemotherapy
The PC group received carboplatin (area under the curve
[AUC] 2) and paclitaxel (45 mg/m2) administered on
days 1, 8, 15, 22, 28, and 35 over a 6-week period [11].
The PE group received 50 mg/m2 of cisplatin adminis-
tered on days 1, 8, 29, and 36, and 50 mg/m2/day of
etoposide delivered on days 1–5 and 29–33 [12].
Radiotherapy
All patients underwent CT planning for three-dimensional
conformal radiotherapy with 6 MV linear accelerator pho-
ton beams. Where available, diagnostic PET images were
fused with the planning CT to help target delineation.
Radiotherapy dose prescriptions ranged from 50 Gy to
70 Gy in 2 Gy per fraction, five fractions a week. Most
patients (92%) were prescribed 60 Gy. Two patients were
prescribed less than 60 Gy because tumor volumes were
deemed too large to meet dose constraints. The gross tumor
volume (GTV) included the primary disease and any
involved regional lymph nodes. Expansions to create clinical
target volumes (CTV) and planning target volumes (PTV)
were based on the treating radiation oncologist’s preference.
The lung dose constraint was specified such that no more
than 35% of the pulmonary parenchyma (defined as total
lung volume minus PTV) received ≥20 Gy. The maximum
point dose allowed for the spinal cord was 50 Gy.
Toxicity
Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria Adverse Events
(CTCAE) version 4.0.
Follow-up and survival data
The follow-up protocol varied between treating physi-
cians. Typically patients were followed up every three to
6 months during the first 2 to 3 years; and 6 months or
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annually thereafter. The frequency of repeat surveillance
CTs and PET were at the physicians’ discretion. The last
follow-up was defined as the most recent visit to the
clinic. Relapse-free survival (RFS) was defined as the time
from the start of CCRT to the first date of disease recur-
rence on imaging or biopsy; patients without relapse were
censored at the last date of follow-up. Local recurrence
was defined as any tumor regrowth in hilar, mediastinal,
or supraclavicular nodes ipsilateral to the primary site of
tumor. OS was defined as the time from the start of
CCRT to death from any cause or last follow-up date.
Dates and causes of death were retrieved from the medi-
cal records and death certificates.
Statistical analysis
All statistical analyses were performed in R statistical
environment (v2.15.2). Differences in patient demograph-
ics between PC- and PE-treated patients were assessed
with chi-squared tests and two-sided Student’s t-tests.
Further differences in RFS and OS were assessed with
Kaplan–Meier survival curves and both univariate and
multivariate Cox proportional hazard ratio (HR) model-
ing analyses followed by the Wald test (survival package
v2.37-4). A P-value <0.05 was considered significant.
Results
Clinicopathological findings
Eighty-three patients were identified from our database.
Of these, eight patients were excluded from analysis: two
patients had excised solitary brain metastases and six
patients did not receive the conventional chemotherapy
doses. Seventy-five patients were subsequently included
for further analyses. The patients in the PC group were
significantly older with a median age of 71 years (range,
44–83) versus 63 years (32–76; P = 0.0006). There was no
difference in clinical stage and histology for patients who
received PC and PE. Other known prognostic variables
such as weight loss, Eastern Cooperative Oncology Group
(ECOG) performance status, comorbidities, and forced
expiratory volume at 1 sec (FEV1) were comparable in
both groups (Table 1).
Staging
All patients underwent a staging CT scan. PET imaging
was performed in 73 of 75 (97%) patients at diagnosis.
Fifty-four patients had clinical stage N2 and N3 on imag-
ing. Of these, biopsy confirmation was undertaken in 27
(50%) patients. Confirmation of mediastinal node
involvement was undertaken via mediastinoscopy in six
cases, endobronchial ultrasound (EBUS) transbronchial
biopsy in eleven cases, and thoracotomy in five cases.
Supraclavicular node biopsy was performed in five cases.
Treatment delivery
The median dose of radiotherapy received in both groups
was 60 Gy with a mean of 58.3 Gy in the PC group and
58.6 Gy in the PE group. Fifty percent (22 of 44) and 58%
(18 of 31) of patients completed the prescribed course of
CCRT in the PC and PE groups, respectively. The relative
mean dose intensities of chemotherapy were comparable in
both the PC and PE groups (carboplatin [90%] and paclit-
axel [89%] vs. cisplatin [84%] and etoposide [86%]). The
most common reasons for not completing the planned
CCRT were radiation esophagitis (nine in PC vs. four in
PE), chest infection (four in PC vs. six in PE), febrile
neutropenia (four in PC vs. one in PE), and hematological
toxicities (four in PC vs. three in PE).
Table 1. Clinical and pathology characteristics of the 75 study
patients.
Characteristics PC (n = 44) PE (n = 31)
n (%) n (%) Pv2/Pt
Age (median [range]) 71 [44–83] 63 [32–76] 0.0006
Sex
Male 35 (80) 20 (65) 0.236
Smoking status
Current 13 (30) 15 (48) 0.234
Former 28 (64) 15 (48)
Never 3 (7) 1 (3)
ECOG 0.232
0 8 (18) 11 (35)
1 33 (75) 18 (58)
2 3 (7) 2 (6)
Charlson morbidity
index (median
[range])
3 [2–6] 2 [2–5] 0.099
Weight loss (>5%) 7 (16) 10 (32) 0.166
FEV1 (median
[range])
1.91 [0.78–3.1] 1.85 [0.79–3.1] 0.896
TLCO (median
[range])
15.8 [6.79–28.3] 15.1 [3.32–30.1] 0.775
Histology 0.548
Squamous 20 (45) 11 (35)
Adenocarcinoma 19 (43) 12 (39)
Large cell 3 (7) 5 (16)
Other 2 (5) 2 (6)
Stage 0.128
3A 34 (77) 18 (58)
3B 10 (23) 13 (42)
n, number; Pv2, chi-squared test; Pt, student t-test; ECOG, Eastern
Cooperative Oncology Group; FEV1, force expiratory volume at 1 sec;
TLCO, transfer factor of the lung for carbon monoxide; PC, carboplatin/
paclitaxel; PE, cisplatin/etoposide.
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Consolidation chemotherapy was given to five patients
in the PE group but none in the PC group (P = 0.022).
Of these five patients, one received docetaxel, another
carboplatin/gemcitabine, and three Stimuvax (Darm-
stadt, Germany) or placebo as part of the phase III
START study (NCT00409188).
Toxicity evaluation
Five (three in PC vs. two in PE, P = 1.000) patients died
from the treatment. Of these, two patients died as a
consequence of chest infection, one died from pneumoni-
tis, and two died from acute coronary syndromes. Treat-
ment-related toxicities are presented in Table 2. The
incidence of all grades pneumonitis was more common in
the PC group (P = 0.033). The PE group had higher rates
of neutropenia and thrombocytopenia (P = 0.024 and
0.039, respectively).
Survival and response
With a median follow-up of 51.6 months, the median OS
for all patients was 18.7 months (95% CI: 14.2–25.9).
Sixty (80%) patients had died at the time of data collec-
tion. Patients receiving PC did do better than patients
receiving PE within 2 years for OS. The median OS
favored the PC group, although this was not significant
(PC 20.7 months vs. PE 13.7 months, P = 0.989) (Fig. 1).
Age and consolidation chemotherapy were the only two
variables statistically different between the PC and PE
group. When adjusted for these two variables, there was
no difference in OS between groups (HR 0.99, 95% CI
0.54–1.83, P = 0.983).
Fifty-two (69%) patients had relapsed disease. The
median RFS was 12 months in the PC group and
11.5 months in the PE group, which was not significant
(HR 1.12, 95% CI 0.63–1.98, P = 0.700) (Fig. 1). Locore-
gional, contralateral relapses, and distant metastases were
observed in 34 (45%), 16 (21%), and 47 (63%) patients,
respectively. Among the 47 patients who had distant
relapse, bone metastases were observed in 16 (34%)
patients and were the most frequent site of distant metas-
tases. This was followed by liver (n = 13, 28%), brain
(n = 12, 26%), and adrenal (n = 4, 9%). There were no
differences in pattern of relapse between both groups.
Twenty-three (44%) (15 in PC and 8 in PE group)
patients received palliative chemotherapy following
progression.
In multivariate analysis, age, sex, smoking status, per-
formance status, comorbidities, histology, stage, type of
chemotherapy regimen, consolidation treatment, and
completion of CCRT were not significantly prognostic for
RFS or OS (Table 3).
Table 2. Nonhematological and hematological adverse events, by
grade (CTCAE 4.0).
Adverse events PC (n = 44) PE (n = 31)
n (%) n (%) Pv2
Esophagitis 0.151
0 7 (16) 8 (26)
1 3 (7) 5 (16)
2 19 (43) 7 (23)
3 10 (23) 10 (32)
4 5 (11) 1 (3)
Pneumonitis 0.033
0 15 (34) 19 (62)
1 21 (48) 4 (13)
2 6 (14) 6 (19)
3 0 (0) 1 (3)
4 1 (2) 1 (3)
5 1 (2) 0 (0)
Neuropathy 0.485
0 42 (96) 0 (0)
1 1 (2) 0 (0)
2 1 (2) 0 (0)
Nephropathy 0.314
0 41 (93) 26 (84)
1 3 (7) 4 (13)
2 0 (0) 0 (0)
3 0 (0) 1 (3)
Nausea/Vomiting 0.291
0 29 (66) 21 (68)
1 7 (16) 7 (23)
2 8 (18) 2 (6)
3 0 (0) 1 (3)
Chest infection 0.534
0 29 (67) 20 (65)
1 1 (2) 0 (0)
2 1 (2) 3 (10)
3 11 (25) 5 (16)
4 1 (2) 2 (6)
5 1 (2) 1 (3)
Neutropenia 0.024
0 29 (66) 17 (55)
1 4 (9) 2 (6)
2 5 (11) 0 (0)
3 6 (14) 8 (26)
4 0 (0) 4 (13)
Febrile neutropenia 0.394
0 39 (89) 25 (81)
3 5 (11) 5 (16)
4 0 (0) 1 (3)
Anemia 0.117
0 26 (60) 11 (36)
1 12 (27) 10 (32)
2 5 (11) 9 (29)
3 1 (2) 0 (0)
4 0 (0) 1 (3)
Thrombocytopenia 0.039
0 40 (91) 23 (74)
1 1 (2) 4 (13)
2 3 (7) 1 (3)
3 0 (0) 3 (10)
Treatment-related deaths 3 (7) 2 (6) 1.000
n, number; Pv2, chi-squared test; PC, carboplatin/paclitaxel; PE,
cisplatin/etoposide.
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Discussion
In this single institution retrospective study, we compared
the toxicity and outcomes of PC and PE with concurrent
chest radiotherapy in patients with unresectable stage III
NSCLC. We found that PC was more likely to be used in
elderly patients but resulted in significantly less hemato-
logical toxicity but a higher risk of radiation pneumonitis.
Despite this, the PC group achieved similar survival
outcomes compared to PE.
Most cancer centers use taxanes or etoposide in combi-
nation with a platinum agent and concurrent chest radio-
therapy to definitively treat unresectable stage III NSCLC.
The median OS in prospective clinical trials using these
regimes ranges from 16 to 22 months for PC [11, 13, 14],
and 15 to 26 months for PE [3, 12, 15–17] (Table 4).
The patients’ median age in these studies was around
63 years, which is considerably younger than our study of
67 years for all patients and 71 years in the PC group.
Our patient cohort comprised “real-world” non-trial
patients, and it was therefore reassuring to demonstrate
similar survival outcomes to that previously reported in
clinical trials.
In the United States, the median age at diagnosis of lung
cancer is 70 years [18] compared with 72 in Australia [19].
Elderly cancer patients may have a relatively lower toler-
ance of chemotherapy because of underlying comorbidities.
This often imposes more medical and physiological chal-
lenges that make the selection of the cytotoxic agent more
difficult. Evidence from randomized controlled trials
focused specifically on older patients is lacking for patients
treated with CCRT. The pivotal Japan Clinical Oncology
Group (JCOG) 0301 trial [20] provided evidence that sin-
gle agent carboplatin with concurrent 60 Gy radiotherapy
(A)
(B)
Figure 1. (A) Overall survival and (B) relapse-free survival Kaplan–
Meier curves. x-axis is truncated at 2.5 years given limited numbers at
risk beyond this point.
Table 3. Multivariate analyses of association between covariates and relapse-free survival and overall survival.
Overall survival Relapse-free survival
Variables HR 95% CI P (Wald test) HR 95% CI P (Wald test)
Age 1.03 0.99–1.06 0.117 1.00 0.97–1.03 0.974
Sex (vs. female) 1.00 0.47–2.14 1.000 0.44 0.19–1.05 0.066
Smoking status (vs. current)
Former/Never 0.75 0.41–1.38 0.355 0.84 0.43–1.67 0.624
ECOG (vs. 0)
1/2 0.92 0.45–1.90 0.826 0.63 0.31–1.30 0.210
Charlson morbidity index 0.90 0.64–1.27 0.566 1.06 0.76–1.50 0.722
Histology (vs. squamous)
Nonsquamous 0.82 0.44–1.52 0.527 1.27 0.66–2.46 0.474
Stage (vs. 3A) 1.15 0.58–2.28 0.681 1.11 0.52–2.36 0.785
Chemo schedule (vs. PE) 0.87 0.47–1.59 0.643 1.38 0.71–2.69 0.338
Completed scheduled CCRT 0.66 0.35–1.26 0.208 1.32 0.66–2.63 0.439
HR, hazard ratio; CI, confidence interval; CCRT, concurrent chemoradiotherapy; PC, carboplatin/paclitaxel; PE, cisplatin/etoposide.
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Table 4. Summary of phase II/III trial results for CCRT with PE and PC regimes for inoperable stage III NSCLC.
Trial Pts (n)
Median
age
(years)
Treatment
schedule Response
Median OS
(months)
(95% CI) Survival% Toxicity
Curran et al. [3]
phase III
187 62 Arm 3: PE +
hypofractionated
RT 69.6 Gy
CR 33% 15.6 (13.0–18.0) 5 years
OS: 13%
Gr ≥ 3 neutropenia 54%
Gr ≥ 3 esophagitis 45%
Gr ≥ 3 pulmonary
toxicity: 17%
Belani et al. [11]
phase II
74 NR Arm 2: induction
PC followed
by concurrent
PC + RT 63 Gy
NR 12.7 (NR) 3 years
OS: 15%
Arm 2:
Gr ≥ 3 neutropenia 16%
Gr ≥ 3 esophagitis 19%
Gr ≥ 3 pneumonitis 4%
92 Arm 3: PC + RT
63 Gy followed
by consolidation PC
16.3 (NR)
(P-values NR)
3 years
OS: 17%
Arm 3:
Gr ≥ 3 neutropenia 26%
Gr ≥ 3 esophagitis 28%
Gr ≥ 3 pneumonitis 16%
Albain et al. [12]
phase II
50 58 PE + RT 61 Gy NR 15 (11–22) 5 years
OS 15%
Gr 4 neutropenia 32%
Gr ≥ 3 esophagitis 20%
Gr ≥ 2 pneumonitis 0%
Yamamoto et al.
[13] phase III
147 63 Arm 3: PC + RT
followed by
consolidation PC
Arm 3: CR
3.4%, PR
59.9%, SD
21.8%, PD
10.9%
22.0 (NR) 5 years
OS 19.5%
Arm 3:
Gr ≥ 3 neutropenia 61.9%
Gr ≥ 3 esophagitis 8.2%
Gr ≥ 3 pneumonitis
4.1% (3 deaths)
Vokes et al.
[14] phase III
182 63 Arm 1: PC +
RT 66 Gy
NR 12 (NR) 3 years
OS 19%
Arm 1:
Gr ≥ 3 neutropenia 15%
Gr ≥ 3 esophagitis 32%
Gr ≥ 3 pneumonitis 4%
184 Arm 2: induction
PC followed
by PC + RT 66 Gy
14 (NR)
(P = 0.3)
3 years
OS 23%
Arm 2:
Gr ≥ 3 neutropenia 31%
Gr ≥ 3 esophagitis 30%
Gr ≥ 3 pneumonitis 10%
Gandara et al.
[15] phase II
83 60 PE + RT 61 Gy
followed by
consolidation
docetaxel
CR 7%
PR 60%
SD 23%
PD 10%
26 (18–35) 3 years
OS 37%
Gr ≥ 3 neutropenia 74%
Gr ≥ 3 esophagitis 17%
Gr ≥ 3 pneumonitis
7% (2 deaths)
Hanna et al.
[16] phase III
73 62 Arm 1: PE +
RT 59.4 Gy
NR 23.2 (NR) 3 years
OS 26.1%
Arm 1:
Gr ≥ 3 neutropenia 32%
Gr ≥ 3 esophagitis 17.2%
Gr ≥ 3 pneumonitis 1.4%
74 Arm 2: PE +
RT 59.4 Gy
followed by
consolidation
docetaxel
21.2 (NR)
(P = 0.883)
3 years
OS 27.1%
Arm 2:
Gr ≥ 3 neutropenia 24.7%
Gr ≥ 3 esophagitis 17.2%
Gr ≥ 3 pneumonitis 9.6%
Kelly et al.
[17] phase III
118 61 Arm1: PE + RT
61 Gy followed
by consolidation
docetaxel
NR 35 (NR) 2 years
OS 59%
For both arms (prior
to randomization):
Gr ≥ 3 neutropenia 43%
125 Arm2: PE + RT 61
Gy followed
by consolidation
docetaxel
followed by
maintenance
gefitinib
23 (NR) 2 years
OS 46%
Gr ≥ 3 esophagitis 14%
Gr ≥ 3 pneumonitis
7% (1 death)
Pts, patients; PC, carboplatin/paclitaxel; PE, cisplatinum/etoposide; MVP, mitomycin/vindesine/cisplatinum; RT, radiotherapy; CR, complete
response; PR, partial response; SD, stable disease; PD, progressive disease; OS, overall survival; NR, not reported.
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is well tolerated and leads to better survival than radiother-
apy alone (HR 0.68, 95% CI 0.47–0.98, P = 0.0179) in
patients older than 70 years with unresectable stage III
NSCLC. As in most prospective clinical trials, the JCOG
0301 was restricted to elderly patients with good perfor-
mance status, limited comorbidities, and stable organ func-
tion. Some retrospective data have also concluded that
CCRT is feasible and improves OS and RFS in elderly but
fit patients with acceptable toxicity [21–23].
Comorbidities in elderly patients with lung cancer are a
prognostic factor for survival and a risk factor for compli-
cations with chemotherapy [22, 24, 25]. Korean investiga-
tors reviewed 125 patients aged ≥70 years receiving
radical radiotherapy with or without concurrent chemo-
therapy for stage III NSCLC and demonstrated that car-
diovascular dysfunction (HR 2.10, 95% CI 1.01–4.39,
P = 0.048) and a simplified comorbidity score (SCS) of
≥10 (HR 1.55, 95% CI 1.16–2.09, P = 0.003) were inde-
pendent prognostic factors for poor survival [25]. There
is no consensus regarding the optimal comorbidity strati-
fication tool for geriatric assessment. The SCS [26] and
CCI [10] are simple and time-effective assessment tools
for cancer patients. Other scoring systems exist, but the
ultimate aim is to ascertain if the patient is to be regarded
as “fit elderly” or “frail elderly” to guide more aggressive
radical treatment. Whether these indices alter outcome in
patients treated with CCRT or whether they can be used
to determine patient suitability has yet to be demon-
strated in prospective studies.
The PC regimen in our study had a higher incidence of
fatal pneumonitis (two patients in PC vs. none in PE),
although the rates for symptomatic pneumonitis (CTCAE
grades 2–4) were lower than the PE group (18% in PC
vs. 25% in PE). Symptomatic radiation pneumonitis is a
clinically important toxicity, occurring in 15–40% of
patients receiving CCRT for NSCLC [27]. Deaths due to
pneumonitis must be viewed seriously but the potential
confounders inevitable in a retrospective study make defi-
nite associations with the type of chemotherapy regimen
difficult. A retrospective study reported a challenge to
confirm the diagnosis of radiation pneumonitis in 48% of
cases due to presence of the confounding factors such as
exacerbation of chronic airway disease, chest infection,
and tumor progression [28]. Nonetheless, a recent meta-
analysis reported that elderly patients who undergo CCRT
with PC are at higher risk of pneumonitis compared to
PE with an odds ratio 3.33 (P < 0.001) [29]. Wang et al.
[8] also showed a higher rate of grade ≥2 pneumonitis in
the PC group compared to PE (48.5% vs. 25%, P = 0.09).
Given this increased rate of pneumonitis it appears perti-
nent to select patients carefully when offering PC.
The increased hematological toxicity in patients treated
with PE also warrants review. In the metastatic NSCLC
setting, Belani et al. [30] reported PE having higher myel-
osuppression rates than the PC regimen. Our finding also
has demonstrated grade ≥3 neutropenia (39% vs. 14%)
and thrombocytopenia (10% vs. none) to be significantly
more prevalent in PE regimen. Considering the toxicity
profile and the similar survival outcomes, the PC regimen
with concurrent chest radiotherapy is a potentially feasible
treatment option in carefully selected elderly patients
despite the presence of multiple comorbidities.
The recent study by Wang et al. [8]. has many similari-
ties with ours, yet showed different results. Their study
demonstrated a significantly improved survival in Chinese
patients treated with concurrent radiotherapy with PE
regimen over PC (20.2 months in PE vs. 13.5 months in
PC, P = 0.04). There was an imbalance in patient charac-
teristics between the PC and PE groups in their study
such that the PC group had more adverse prognostic
characteristics including weight loss, age, and anemia,
although these differences did not reach statistical signifi-
cance. More patients in the PE group received the stan-
dard dose of radiotherapy (≥60 Gy) and consolidation
chemotherapy, which could also potentially imbalance the
favorable survival outcome seen in this study [8].
Despite the survival difference observed by Wang et al.
[8], the PC regimen still remains widely used both in
clinical practice and also as a comparator group in clini-
cal trials. Firstly, the PC regimen has repeatedly shown
similar efficacy and better tolerability when compared to
the PE regimen. The recent Radiation Thoracic Oncology
Group (RTOG) 0617 study[6] demonstrated a median
survival for Stage III NSCLC patients receiving thoracic
radiotherapy and concurrent weekly PC with or without
cetuximab of 20.7 months, which was better than the vin-
blastine/cisplatin (17 months) and cisplatin/oral etoposide
(15.6 months) regimens used in the preceding RTOG
9410 study [3]. In the setting of palliative chemotherapy
for metastatic NSCLC, Belani et al. [30] reported similar
efficacy and outcomes between PC and PE, but patients
receiving the third generation PC regimen had lower tox-
icities and better quality of life. Similarly in the neoadju-
vant context, Machtay et al. [31] showed that PC, when
compared to PE, achieved similar pathological response
rates and survival outcomes in patients with locally
advanced stage III NSCLC treated with CCRT, but the
PC regimen was associated with less grade 3 gastrointesti-
nal toxicities (3% vs. 27%, P = 0.02). Secondly, tumor
biology in Asian and non-Asian populations is different.
In the last decade, there has been considerable interest on
the identification of patients with activating epidermal
growth factor receptor mutations (EGFRmut). The pres-
ence of an EGFRmut is not only favorably prognostic but
also predictive for progression-free survival and increased
control rates when treated with tyrosine kinase inhibitors
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but also chemotherapy [32]. In the setting of radiother-
apy, patients with EGFRmut were also found to have more
radiosensitive tumors and had decreased local recurrence
rates [33]. The frequency of EGFRmut in Caucasian popu-
lations is approximately 15% while the rate is reported to
be much higher, up to 50%, in Asian patients [34].
Our study has several limitations. The retrospective
nature does not allow for accurate quantification of the
severity of the toxicities and does not capture subjective
toxicities including lethargy and neuropathy. Nevertheless,
the grading for pneumonitis, hematological, and esopha-
gitis toxicities and other serious adverse events were
robust because of regular clinician and dietitian follow-up
and routine blood tests before each session of chemother-
apy. Secondly, the number of patients was relatively small,
thus limiting the analysis of prognostic and predictive fac-
tors. Thirdly, the posttreatment follow-up protocol varied
between patients. Consequently, the relapse-free interval
may be overappreciated, although OS was accurate given
the lost to follow-up rate in this study was relatively low
(four patients) in this study.
In conclusion, we report on the toxicities and clinical
outcomes of patients with unresectable stage III NSCLC
treated with concurrent chest radiotherapy with either PC
or PE. Given that PC was used predominantly in older
patients but resulted in less toxicities but equivalent
survival, we believe PC warrants further investigation in
randomized studies involving older patients. However, the
poor OS with both treatments requires better strategies to
improve clinical outcome of patients with unresectable
locally advanced NSCLC.
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